What is BLTE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 5.98B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BLTE?

P/E (TTM) is n/a and 52-week range is $77.64 to $200.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BLTE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BLTE?

The company profile lists net income (TTM) near $-107M, EPS (TTM) near $-2.85 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Belite Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 37.5M shares outstanding, ISIN US07782B1044 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Belite Bio Inc

$BLTE

Health Care · Pharmaceuticals

IR Run Scenarios

$151.87

-4.24%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Belite Bio, Inc. engages in the research and development of drugs. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2022-04-29. The firm is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Employees

Website

belitebio.com/

IPO

2022-04-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)